 | |
| Company type | Subsidiary |
|---|---|
| Nasdaq: CELG | |
| Industry | Biotechnology |
| Founded | 1986 |
| Founder | Sol J. Barer |
| Headquarters | Summit, New Jersey, U.S. |
Key people | Robert J. Hugin (executive chairman) Mark Alles (CEO) |
| Products | Revlimid Abraxane Pomalyst/Imnovid Thalomid Idhifa |
| Revenue |  $15.281 billion (2018) |
| $4.046 billion (2018) | |
| Total assets | $35.480 billion (2018) |
| Total equity |  $6.161 billion (2018) |
Number of employees | 8,852 (2018) |
| Parent | Bristol Myers Squibb |
| Website | www |
| Footnotes / references [1] | |
Celgene Corporation is a pharmaceutical company that makes cancer and immunology drugs. Its major product is Revlimid (lenalidomide), which is used in the treatment of multiple myeloma, and also in certain anemias. The company is incorporated in Delaware, headquartered in Summit, New Jersey, and a subsidiary of Bristol Myers Squibb (BMS).[2]
- ^ "Celgene Corporation 2018 Form 10-K Annual Report". U.S. Securities and Exchange Commission.
- ^ Bristol-Myers Squibb Completes Acquisition of Celgene, Creating a Leading Biopharma Company, PM BMS, November 20, 2019; retrieved May 20, 2020